中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (4): 291-293.doi: 10.12007/j.issn.0258-4646.2018.04.001

• 论著 •    下一篇

贝伐珠单抗联合卡铂与贝伐珠单抗单药治疗恶性胸腔积液的疗效和安全性

赵健竹1, 汤隽2, 马洁韬1, 张树玲1, 韩琤波1, 邹华伟1   

  1. 1. 中国医科大学附属盛京医院第一肿瘤科, 沈阳 110022;
    2. 中国医科大学附属盛京医院第一胸外科, 沈阳 110004
  • 收稿日期:2017-12-21 出版日期:2018-04-30 发布日期:2018-04-10
  • 通讯作者: 韩琤波 E-mail:hancb@sj-hospital.org
  • 作者简介:赵健竹(1986-),女,主治医师,博士.
  • 基金资助:
    国家自然科学基金青年科学基金(81501990);辽宁省高等学校杰出青年学者成长计划(LJQ2014082)

Efficacy and Safety of Combined Bevacizumab and Carboplatin Therapy and Bevacizumab Monotherapy for the Treatment of Malignant Pleural Effusion

ZHAO Jianzhu1, TANG Jun2, MA Jietao1, ZHANG Shuling1, HAN Chengbo1, ZOU Huawei1   

  1. 1. Department of Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China;
    2. Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang 110004, China
  • Received:2017-12-21 Online:2018-04-30 Published:2018-04-10

摘要: 目的 比较贝伐珠单抗联合卡铂与贝伐珠单抗单药通过胸腔灌注的方法治疗恶性胸腔积液的临床疗效及不良反应,为恶性胸腔积液治疗决策提供初步依据。方法 回顾性收集2015年1月至2016年11月我院收治的合并恶性胸腔积液的晚期肿瘤患者的临床资料,符合纳入标准的患者共48例,所有患者均经胸水细胞病理学或影像学证实为恶性胸腔积液,分为贝伐珠单抗联合卡铂组(30例)和贝伐珠单抗单药治疗组(18例),记录患者体力状况改善、影像学改变以及恶心呕吐、粒细胞减少等不良反应,比较2组治疗效果及不良反应的差异。结果 贝伐珠单抗联合卡铂治疗组和贝伐珠单抗单药治疗组中治疗有效率分别为83.3%和55.6%,3~4级不良反应发生率分别为40.0%和11.1%,差异均有统计学意义(P=0.039,P=0.033)。在生活质量改善方面,2组比较无统计学差异(P=0.113)。贝伐珠单抗联合卡铂治疗组和贝伐珠单抗单药治疗组中位疾病进展时间分别为3.9和3.5个月,差异无统计学意义(P=0.873),且在生活质量改善方面,2组比较无统计学差异(P=0.113)。结论 贝伐珠单抗联合卡铂治疗恶性胸腔积液有效率较高,但与贝伐珠单抗单药灌注治疗相比不良反应较大,二者在疾病进展时间及改善生活质量方面无统计学差异,在临床选择中需要根据患者具体情况选择适合的治疗策略。

关键词: 贝伐珠单抗, 恶性胸腔积液, 恶性肿瘤, 胸腔灌注

Abstract: Objective To explore the efficacy and side effects of combined bevacizumab and carboplatin therapy and bevacizumab monotherapy for the treatment of malignant pleural effusion (MPE) through thoracic perfusion,and provide evidence for a clinical strategy. Methods We retrospectively collected 48 patients with malignant pleural effusion caused by advanced tumor effusion from January 2015 to November 2016 according to the inclusion criteria. All patients were diagnosed based on cell pathology or imaging. Patients received combined bevacizumab and carboplatin therapy (n=30) or bevacizumab monotherapy (n=18). The differences in clinical improvement,changes in images,symptoms of nausea and vomiting,neutrophil count reduction,and other side effects were compared between the two groups. Results There were significant differences in the efficacy (83.3% and 55.6%,respectively;P=0.039) and rates of grade 3 side effects (40.0% and 11.1%,respectively;P=0.033) between the combined therapy and monotherapy groups. No significant difference in quality of life improvement was found between the two groups (P=0.113). The median times to progression in combined therapy and monotherapy groups were 3.9 and 3.5 months,respectively,without statistical significance (P=0.873). Conclusion Compared with bevacizumab monotherapy,combined bevacizumab and carboplatin therapy is highly effective for the treatment of MPE with more severe side effects. There are no significant differences in the time to progression and quality of life improvement between these two therapies. We should choose appropriate therapeutic drugs according to specific patients in the clinic.

Key words: bevacizumab, malignant pleural effusion, malignant tumor, pleural perfusion

中图分类号: 

  • R730.53
[1] 张玉,尤庆山,孙迪,等. 恶性胸腔积液综合治疗进展[J]. 现代生物医学进展,2012,12(17):3358-3361. DOI:10.13241/j.cnki.pmb.2012.17.048.
[2] BRADSHAW M,MANSFIELD A,PEIKERT T. The role of vascular endothelial growth factor in the pathogenesis,diagnosis and treatment of malignant pleural effusion[J]. Curr Oncol Rep,2013,15(3):207-216. DOI:10.1177/1947601910389605.
[3] MASAGO K,FUJIMOTO D,FUJITA S,et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer[J]. Mol Clin Oncol,2015,3(2):415-419. DOI:10.3892/mco.2014.457.
[4] KITAMURA K,KUBOTA K,ANDO M,et al. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion[J]. Cancer Chemother Pharmacol, 2013,71(2):457-461. DOI:10.1007/s00280-012-2026-4.
[5] ZHAO H,LI X,CHEN D,et al. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer:results of a phase Ⅲ clinical trial[J]. Med Oncol,2015,32(2):292. DOI:10.1007/s12032-014-0292-1.
[6] PORCEL JM. Malignant pleural effusions because of lung cancer[J]. Curr Opin Pulm Med,2016,22(4):356-361. DOI:10.1097/MCP.0000000000000264.
[7] EGAN AM,MCPHILLIPS D,SARKAR S,et al. Malignant pleural effusion[J]. QJM,2014,107(3):179-184. DOI:10.1093/qjmed/hct245.
[8] KASTELIK J A. Management of malignant pleural effusion[J]. Lung, 2013,191(2):165-175. DOI:10.1007/s00408-012-9445-1.
[9] 施焕中. 规范恶性胸腔积液的诊断与治疗[J]. 中华内科杂志, 2014,53(3):166-167. DOI:10.3760/cma.j.issn.0578-1426.2014.03.003.
[10] CHEN D,LI X,ZHAO H,et al. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion[J]. Indian J Cancer,2014, 51(Suppl 3):e82-e85. DOI:10.4103/0019-509X.154058.
[11] LI Q,YAN H,ZHAO P,et al. Efficacy and safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer:a meta-analysis of randomized controlled trials[J]. Sci Rep,2015,5:15746. DOI:10.1038/srep15746.
[12] RIBEIRO SC,VARGAS FS,ANTONANGELO L,et al. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion[J]. Respirology,2009,14(8):1188-1193. DOI:10.1111/j.1440-1843.2009.01628.
[13] ARAVANTINOS G,PECTASIDES D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer:a systematic review[J]. J Ovarian Res,2014,7:57. DOI:10.1186/1757-2215-7-57.
[14] FIELD KM,JORDAN JT,WEN PY,et al. Bevacizumab and glioblastoma:scientific review,newly reported updates,and ongoing controversies[J]. Cancer,2015,121(7):997-1007. DOI:10.1002/cncr.28935.
[15] JIANG L,LI P,GONG Z,et al. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin[J]. Anticancer Res,2016,36(3):1313-1318.
[16] TAMIYA M,TAMIYA A,YASUE T,et al. Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus carboplatin-paclitaxel treatment for non-small cell lung cancer with malignant pleural effusion[J]. Anticancer Res,2016,36(6):2939-2944.
[17] CHEN D,SONG X,SHI F,et al. Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion[J]. Oncotarget,2017, 8(21):35262-35271. DOI:10.18632/oncotarget.13064.
[18] 迟晶,白阳,陈虹. 贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J]. 中国临床药理学杂志,2016,32(13):1175-1177. DOI:10.13699/j.cnki.1001-6821.2016.13.007.
[19] 杨震,刘萍萍,李薇,等. 贝伐单抗单药腔内灌注治疗难治性恶性胸腹腔积液临床观察[J]. 安徽医药,2015,19(6):1175-1176. DOI:10.3969/j.issn.1009-6469.2015.06.051.
[20] 曲博,姜威,周志明. 贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J]. 中国医科大学学报,2015,44(7):648-652. DOI:10.3969/j.issn.0258-4646.2015.07.018.
[21] 林凤华,苏伟平,金润女. 贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液临床研究[J]. 临床军医杂志,2016,44(7):698-700. DOI:10.16680/j.1671-3826.2016.07.11.
[1] 徐昕, 刘利. 血液系统恶性肿瘤患者D型人格、领悟社会支持与创伤后应激障碍症状的关系[J]. 中国医科大学学报, 2018, 47(5): 443-447,453.
[2] 王园,田野,刘思洋,赵希彤,姜文军,田大力. 血管内皮生长因子及其受体在伴恶性胸腔积液非小细胞肺癌组织中的表达[J]. 中国医科大学学报, 2016, 45(5): 441-444.
[3] 田野,王园,刘思洋,姜文军,田大力. 肺癌伴恶性胸腔积液中EGFR 突变检测及其临床意义[J]. 中国医科大学学报, 2016, 45(2): 150-153.
[4] 徐亮,马刚,葛春林,陈秀秀,宋少伟,许元鸿,郭克建,刘哲. 消化系统恶性肿瘤合并抗利尿激素分泌异常综合征的临床分析[J]. 中国医科大学学报, 2016, 45(12): 1142-1144.
[5] 曲博,姜威,周志明. 贝伐单抗联合顺铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J]. 中国医科大学学报, 2015, 44(7): 648-652.
[6] 胡艳芬,,陈龙,荆超 ,,谢贤和. 流式细胞术检测DNA倍体数对鉴别良恶性肿瘤价值的Meta分析[J]. 中国医科大学学报, 2015, 44(2): 136-142.
[7] 刘阳. 树突状细胞联合细胞因子诱导的杀伤细胞免疫治疗恶性肿瘤患者的护理[J]. 中国医科大学学报, 2015, 44(2): 184-185.
[8] 薛东炜,刘春来,张西玲,王平. 肿瘤用输尿管支架管治疗恶性输尿管梗阻的临床应用[J]. 中国医科大学学报, 2014, 43(5): 468-469.
[9] 陶春梅,王学梅,张义侠,陈波,. 超声引导网膜活检在卵巢恶性肿瘤术前诊断中的应用[J]. 中国医科大学学报, 2013, 42(5): 466-468.
[10] 刘梅,朱红,尹新江,何春涤. 皮肤基底细胞癌和鳞状细胞癌856例回顾性分析[J]. 中国医科大学学报, 2013, 42(12): 1099-1101.
[11] 胡玥, 韩佳利 ,丁晓旭 ,郭燕 ,阎艾慧. 上颌窦内酷似恶性肿瘤的出血性息肉的临床诊治分析(附3例报道)[J]. 中国医科大学学报, 2012, 41(4): 379-379.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA